ID   ITA4_HUMAN              Reviewed;        1032 AA.
AC   P13612; D3DPG4; Q7Z4L6;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 3.
DT   07-APR-2021, entry version 215.
DE   RecName: Full=Integrin alpha-4;
DE   AltName: Full=CD49 antigen-like family member D;
DE   AltName: Full=Integrin alpha-IV;
DE   AltName: Full=VLA-4 subunit alpha;
DE   AltName: CD_antigen=CD49d;
DE   Flags: Precursor;
GN   Name=ITGA4; Synonyms=CD49D;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2788572; DOI=10.1002/j.1460-2075.1989.tb03516.x;
RA   Takada Y., Elices M.J., Crouse C., Hemler M.E.;
RT   "The primary structure of the alpha 4 subunit of VLA-4: homology to other
RT   integrins and a possible cell-cell adhesion function.";
RL   EMBO J. 8:1361-1368(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1551405; DOI=10.1002/eji.1830220434;
RA   Rubio M., Nueda A., Vara A., Corbi-Lopez A.L.;
RT   "A single mRNA encodes the alpha 150 and alpha 80/70 forms of the alpha
RT   subunit of VLA4.";
RL   Eur. J. Immunol. 22:1099-1102(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLN-878.
RX   PubMed=8643114; DOI=10.1016/0161-5890(96)00001-6;
RA   Szabo M.C., McIntyre B.W.;
RT   "Identification of two variants of the human integrin alpha 4 subunit.";
RL   Mol. Immunol. 32:1453-1454(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLN-878.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-87 (ISOFORM 1).
RX   PubMed=2034655; DOI=10.1073/pnas.88.10.4094;
RA   Rosen G.D., Birkenmeier T.M., Dean D.C.;
RT   "Characterization of the alpha 4 integrin gene promoter.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:4094-4098(1991).
RN   [8]
RP   PROTEIN SEQUENCE OF 34-47.
RX   PubMed=3033641; DOI=10.1073/pnas.84.10.3239;
RA   Takada Y., Strominger J.L., Hemler M.E.;
RT   "The very late antigen family of heterodimers is part of a superfamily of
RT   molecules involved in adhesion and embryogenesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:3239-3243(1987).
RN   [9]
RP   PROTEIN SEQUENCE OF 592-601, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF
RP   LYS-590 AND ARG-591.
RX   PubMed=1730718;
RA   Teixido J., Parker C.M., Kassner P.D., Hemler M.E.;
RT   "Functional and structural analysis of VLA-4 integrin alpha 4 subunit
RT   cleavage.";
RL   J. Biol. Chem. 267:1786-1791(1992).
RN   [10]
RP   DOMAIN, AND INTERACTION WITH CSPG4.
RX   PubMed=9488735; DOI=10.1074/jbc.273.10.5955;
RA   Iida J., Meijne A.M.L., Oegema T.R. Jr., Yednock T.A., Kovach N.L.,
RA   Furcht L.T., McCarthy J.B.;
RT   "A role of chondroitin sulfate glycosaminoglycan binding site in
RT   alpha4beta1 integrin-mediated melanoma cell adhesion.";
RL   J. Biol. Chem. 273:5955-5962(1998).
RN   [11]
RP   INTERACTION WITH PXN; LPXN AND TGFB1I1, AND MUTAGENESIS OF TYR-1024.
RX   PubMed=10604475; DOI=10.1038/45264;
RA   Liu S., Thomas S.M., Woodside D.G., Rose D.M., Kiosses W.B., Pfaff M.,
RA   Ginsberg M.H.;
RT   "Binding of paxillin to alpha4 integrins modifies integrin-dependent
RT   biological responses.";
RL   Nature 402:676-681(1999).
RN   [12]
RP   PHOSPHORYLATION AT SER-1021, AND MUTAGENESIS OF SER-1021.
RX   PubMed=11533025; DOI=10.1074/jbc.m102665200;
RA   Han J., Liu S., Rose D.M., Schlaepfer D.D., McDonald H., Ginsberg M.H.;
RT   "Phosphorylation of the integrin alpha 4 cytoplasmic domain regulates
RT   paxillin binding.";
RL   J. Biol. Chem. 276:40903-40909(2001).
RN   [13]
RP   INTERACTION WITH MDK.
RX   PubMed=15466886; DOI=10.1242/jcs.01423;
RA   Muramatsu H., Zou P., Suzuki H., Oda Y., Chen G.Y., Sakaguchi N.,
RA   Sakuma S., Maeda N., Noda M., Takada Y., Muramatsu T.;
RT   "alpha4beta1- and alpha6beta1-integrins are functional receptors for
RT   midkine, a heparin-binding growth factor.";
RL   J. Cell Sci. 117:5405-5415(2004).
RN   [14]
RP   FUNCTION, AND MUTAGENESIS OF THR-222 AND GLY-223.
RX   PubMed=18635536; DOI=10.1074/jbc.m804835200;
RA   Saegusa J., Akakura N., Wu C.Y., Hoogland C., Ma Z., Lam K.S., Liu F.T.,
RA   Takada Y.K., Takada Y.;
RT   "Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins
RT   alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in
RT   an integrin-dependent manner.";
RL   J. Biol. Chem. 283:26107-26115(2008).
RN   [15]
RP   FUNCTION IN LEUKOCYTE TO ENDOTHELIAL CELLS ADHESION, AND INTERACTION WITH
RP   JAML.
RX   PubMed=19064666; DOI=10.1083/jcb.200805061;
RA   Luissint A.C., Lutz P.G., Calderwood D.A., Couraud P.O., Bourdoulous S.;
RT   "JAM-L-mediated leukocyte adhesion to endothelial cells is regulated in cis
RT   by alpha4beta1 integrin activation.";
RL   J. Cell Biol. 183:1159-1173(2008).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-480; ASN-518; ASN-538 AND
RP   ASN-645.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-linked
RT   cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1021, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   FUNCTION, BINDING TO CX3CL1, AND IDENTIFICATION IN A COMPLEX WITH CX3CR1
RP   AND CX3CL1.
RX   PubMed=23125415; DOI=10.4049/jimmunol.1200889;
RA   Fujita M., Takada Y.K., Takada Y.;
RT   "Integrins alphavbeta3 and alpha4beta1 act as coreceptors for fractalkine,
RT   and the integrin-binding defective mutant of fractalkine is an antagonist
RT   of CX3CR1.";
RL   J. Immunol. 189:5809-5819(2012).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1021, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   FUNCTION.
RX   PubMed=25398877; DOI=10.1074/jbc.m114.579946;
RA   Fujita M., Zhu K., Fujita C.K., Zhao M., Lam K.S., Kurth M.J., Takada Y.K.,
RA   Takada Y.;
RT   "Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces
RT   integrin activation through direct binding to a newly identified binding
RT   site (site 2) in integrins alphavbeta3, alpha4beta1, and alpha5beta1.";
RL   J. Biol. Chem. 290:259-271(2015).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are
CC       receptors for fibronectin. They recognize one or more domains within
CC       the alternatively spliced CS-1 and CS-5 regions of fibronectin. They
CC       are also receptors for VCAM1. Integrin alpha-4/beta-1 recognizes the
CC       sequence Q-I-D-S in VCAM1. Integrin alpha-4/beta-7 is also a receptor
CC       for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated
CC       endothelial cells integrin VLA-4 triggers homotypic aggregation for
CC       most VLA-4-positive leukocyte cell lines. It may also participate in
CC       cytolytic T-cell interactions with target cells. ITGA4:ITGB1 binds to
CC       fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent
CC       fractalkine signaling (PubMed:23125415). ITGA4:ITGB1 binds to PLA2G2A
CC       via a site (site 2) which is distinct from the classical ligand-binding
CC       site (site 1) and this induces integrin conformational changes and
CC       enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877).
CC       {ECO:0000269|PubMed:18635536, ECO:0000269|PubMed:19064666,
CC       ECO:0000269|PubMed:23125415, ECO:0000269|PubMed:25398877}.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit. The alpha subunit
CC       can sometimes be cleaved into two non-covalently associated fragments.
CC       Alpha-4 associates with either beta-1 or beta-7. Alpha-4 interacts with
CC       PXN, LPXN, and TGFB1I1/HIC5. Interacts with CSPG4 through CSPG4
CC       chondroitin sulfate glycosaminoglycan. Interacts with JAML; integrin
CC       alpha-4/beta-1 may regulate leukocyte to endothelial cells adhesion by
CC       controlling JAML homodimerization. ITGA4:ITGB1 is found in a ternary
CC       complex with CX3CR1 and CX3CL1 (PubMed:23125415). Interacts with MDK
CC       (PubMed:15466886). ITGA4:ITGB1 interacts with MDK; this interaction
CC       mediates MDK-induced osteoblast cells migration through PXN
CC       phosphorylation (PubMed:15466886). {ECO:0000269|PubMed:10604475,
CC       ECO:0000269|PubMed:15466886, ECO:0000269|PubMed:19064666,
CC       ECO:0000269|PubMed:23125415, ECO:0000269|PubMed:9488735}.
CC   -!- INTERACTION:
CC       P13612; Q8IZP0-2: ABI1; NbExp=2; IntAct=EBI-703044, EBI-7358775;
CC       P13612; P05556: ITGB1; NbExp=4; IntAct=EBI-703044, EBI-703066;
CC       P13612; P26010: ITGB7; NbExp=6; IntAct=EBI-703044, EBI-702932;
CC       P13612; P49023: PXN; NbExp=4; IntAct=EBI-703044, EBI-702209;
CC       P13612; O43294: TGFB1I1; NbExp=2; IntAct=EBI-703044, EBI-1051449;
CC       P13612; P84092: Ap2m1; Xeno; NbExp=2; IntAct=EBI-703044, EBI-297693;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P13612-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P13612-2; Sequence=VSP_056612, VSP_056613;
CC   -!- DOMAIN: The SG1 motif is involved in binding to chondroitin sulfate
CC       glycosaminoglycan and cell adhesion. {ECO:0000269|PubMed:9488735}.
CC   -!- PTM: Phosphorylation on Ser-1027 inhibits PXN binding.
CC       {ECO:0000269|PubMed:11533025}.
CC   -!- SIMILARITY: Belongs to the integrin alpha chain family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB59613.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=CAA34852.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X16983; CAA34852.1; ALT_FRAME; mRNA.
DR   EMBL; L12002; AAB59613.1; ALT_FRAME; mRNA.
DR   EMBL; AC020595; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471058; EAX10985.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX10987.1; -; Genomic_DNA.
DR   EMBL; BC055419; AAH55419.1; -; mRNA.
DR   CCDS; CCDS42788.1; -. [P13612-1]
DR   CCDS; CCDS82540.1; -. [P13612-2]
DR   PIR; S06046; S06046.
DR   RefSeq; NP_000876.3; NM_000885.5. [P13612-1]
DR   RefSeq; NP_001303241.1; NM_001316312.1. [P13612-2]
DR   PDB; 3V4P; X-ray; 3.15 A; A/C=34-620.
DR   PDB; 3V4V; X-ray; 3.10 A; A/C=34-620.
DR   PDB; 4HKC; X-ray; 2.20 A; B=1003-1032.
DR   PDB; 5C7Z; X-ray; 2.77 A; B=1008-1015.
DR   PDB; 5FPI; X-ray; 2.77 A; B=1008-1015.
DR   PDBsum; 3V4P; -.
DR   PDBsum; 3V4V; -.
DR   PDBsum; 4HKC; -.
DR   PDBsum; 5C7Z; -.
DR   PDBsum; 5FPI; -.
DR   BMRB; P13612; -.
DR   SMR; P13612; -.
DR   BioGRID; 109883; 519.
DR   ComplexPortal; CPX-1802; Integrin alpha4-beta1 complex.
DR   ComplexPortal; CPX-1823; Integrin alpha4-beta7 complex.
DR   CORUM; P13612; -.
DR   DIP; DIP-34971N; -.
DR   IntAct; P13612; 29.
DR   STRING; 9606.ENSP00000380227; -.
DR   BindingDB; P13612; -.
DR   ChEMBL; CHEMBL278; -.
DR   DrugBank; DB04997; ATL1102.
DR   DrugBank; DB05092; CDP323.
DR   DrugBank; DB15791; MK-0668.
DR   DrugBank; DB00108; Natalizumab.
DR   DrugBank; DB05122; R1295.
DR   DrugBank; DB05468; R411.
DR   DrugBank; DB06822; Tinzaparin.
DR   DrugBank; DB09033; Vedolizumab.
DR   DrugCentral; P13612; -.
DR   GuidetoPHARMACOLOGY; 2443; -.
DR   GlyGen; P13612; 12 sites.
DR   iPTMnet; P13612; -.
DR   PhosphoSitePlus; P13612; -.
DR   BioMuta; ITGA4; -.
DR   DMDM; 311033436; -.
DR   EPD; P13612; -.
DR   jPOST; P13612; -.
DR   MassIVE; P13612; -.
DR   MaxQB; P13612; -.
DR   PaxDb; P13612; -.
DR   PeptideAtlas; P13612; -.
DR   PRIDE; P13612; -.
DR   ProteomicsDB; 52943; -. [P13612-1]
DR   ProteomicsDB; 69208; -.
DR   ABCD; P13612; 17 sequenced antibodies.
DR   Antibodypedia; 10886; 2017 antibodies.
DR   DNASU; 3676; -.
DR   Ensembl; ENST00000339307; ENSP00000340149; ENSG00000115232. [P13612-2]
DR   Ensembl; ENST00000397033; ENSP00000380227; ENSG00000115232. [P13612-1]
DR   GeneID; 3676; -.
DR   KEGG; hsa:3676; -.
DR   UCSC; uc002unu.4; human. [P13612-1]
DR   CTD; 3676; -.
DR   DisGeNET; 3676; -.
DR   GeneCards; ITGA4; -.
DR   HGNC; HGNC:6140; ITGA4.
DR   HPA; ENSG00000115232; Tissue enhanced (blood, lymphoid tissue).
DR   MIM; 192975; gene.
DR   neXtProt; NX_P13612; -.
DR   OpenTargets; ENSG00000115232; -.
DR   PharmGKB; PA29940; -.
DR   VEuPathDB; HostDB:ENSG00000115232.13; -.
DR   eggNOG; KOG3637; Eukaryota.
DR   GeneTree; ENSGT00940000158443; -.
DR   HOGENOM; CLU_1639373_0_0_1; -.
DR   InParanoid; P13612; -.
DR   OMA; CSVGYIY; -.
DR   OrthoDB; 189377at2759; -.
DR   PhylomeDB; P13612; -.
DR   TreeFam; TF105391; -.
DR   PathwayCommons; P13612; -.
DR   Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-8949275; RUNX3 Regulates Immune Response and Cell Migration.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   SignaLink; P13612; -.
DR   SIGNOR; P13612; -.
DR   BioGRID-ORCS; 3676; 23 hits in 989 CRISPR screens.
DR   ChiTaRS; ITGA4; human.
DR   GeneWiki; CD49d; -.
DR   GenomeRNAi; 3676; -.
DR   Pharos; P13612; Tclin.
DR   PRO; PR:P13612; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P13612; protein.
DR   Bgee; ENSG00000115232; Expressed in monocyte and 145 other tissues.
DR   ExpressionAtlas; P13612; baseline and differential.
DR   Genevisible; P13612; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0034668; C:integrin alpha4-beta1 complex; TAS:ARUK-UCL.
DR   GO; GO:0034669; C:integrin alpha4-beta7 complex; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IMP:UniProtKB.
DR   GO; GO:0015026; F:coreceptor activity; TAS:UniProtKB.
DR   GO; GO:0001968; F:fibronectin binding; IEA:Ensembl.
DR   GO; GO:0005178; F:integrin binding; TAS:ARUK-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:1990405; F:protein antigen binding; IEA:Ensembl.
DR   GO; GO:0060385; P:axonogenesis involved in innervation; IEA:Ensembl.
DR   GO; GO:0030183; P:B cell differentiation; IC:BHF-UCL.
DR   GO; GO:0140039; P:cell-cell adhesion in response to extracellular stimulus; IGI:ARUK-UCL.
DR   GO; GO:0033631; P:cell-cell adhesion mediated by integrin; IGI:ARUK-UCL.
DR   GO; GO:0007160; P:cell-matrix adhesion; IMP:UniProtKB.
DR   GO; GO:0003366; P:cell-matrix adhesion involved in ameboidal cell migration; IMP:UniProtKB.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; IGI:ARUK-UCL.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; IEA:Ensembl.
DR   GO; GO:1990771; P:clathrin-dependent extracellular exosome endocytosis; IEA:Ensembl.
DR   GO; GO:0050904; P:diapedesis; IEA:Ensembl.
DR   GO; GO:0035987; P:endodermal cell differentiation; IEP:UniProtKB.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0034113; P:heterotypic cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:0098657; P:import into cell; IEA:Ensembl.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0050901; P:leukocyte tethering or rolling; IMP:UniProtKB.
DR   GO; GO:0090074; P:negative regulation of protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:1990138; P:neuron projection extension; IEA:Ensembl.
DR   GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; IMP:BHF-UCL.
DR   GO; GO:1903238; P:positive regulation of leukocyte tethering or rolling; IEA:Ensembl.
DR   GO; GO:2000406; P:positive regulation of T cell migration; IEA:Ensembl.
DR   GO; GO:1905564; P:positive regulation of vascular endothelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0043113; P:receptor clustering; IMP:UniProtKB.
DR   GO; GO:0050776; P:regulation of immune response; TAS:Reactome.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IMP:UniProtKB.
DR   Gene3D; 2.130.10.130; -; 1.
DR   IDEAL; IID00615; -.
DR   InterPro; IPR013517; FG-GAP.
DR   InterPro; IPR013519; Int_alpha_beta-p.
DR   InterPro; IPR000413; Integrin_alpha.
DR   InterPro; IPR013649; Integrin_alpha-2.
DR   InterPro; IPR018184; Integrin_alpha_C_CS.
DR   InterPro; IPR028994; Integrin_alpha_N.
DR   InterPro; IPR032695; Integrin_dom_sf.
DR   Pfam; PF01839; FG-GAP; 2.
DR   Pfam; PF08441; Integrin_alpha2; 1.
DR   PRINTS; PR01185; INTEGRINA.
DR   SMART; SM00191; Int_alpha; 5.
DR   SUPFAM; SSF69179; SSF69179; 3.
DR   PROSITE; PS51470; FG_GAP; 7.
DR   PROSITE; PS00242; INTEGRIN_ALPHA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell adhesion;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Integrin;
KW   Membrane; Metal-binding; Phosphoprotein; Receptor; Reference proteome;
KW   Repeat; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..33
FT                   /evidence="ECO:0000269|PubMed:3033641"
FT   CHAIN           34..1032
FT                   /note="Integrin alpha-4"
FT                   /id="PRO_0000016244"
FT   TOPO_DOM        35..977
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        978..1001
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1002..1032
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REPEAT          35..100
FT                   /note="FG-GAP 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   REPEAT          110..177
FT                   /note="FG-GAP 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   REPEAT          185..237
FT                   /note="FG-GAP 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   REPEAT          238..291
FT                   /note="FG-GAP 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   REPEAT          292..351
FT                   /note="FG-GAP 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   REPEAT          355..412
FT                   /note="FG-GAP 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   REPEAT          416..478
FT                   /note="FG-GAP 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00803"
FT   CA_BIND         314..322
FT                   /evidence="ECO:0000255"
FT   CA_BIND         377..385
FT                   /evidence="ECO:0000255"
FT   CA_BIND         439..447
FT                   /evidence="ECO:0000255"
FT   MOTIF           606..616
FT                   /note="SG1"
FT   MOTIF           1003..1007
FT                   /note="GFFKR motif"
FT   SITE            591..592
FT                   /note="Cleavage"
FT   MOD_RES         1021
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11533025,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:24275569"
FT   CARBOHYD        79
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        138
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        229
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        480
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19349973"
FT   CARBOHYD        518
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19349973"
FT   CARBOHYD        538
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19349973"
FT   CARBOHYD        626
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        645
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19349973"
FT   CARBOHYD        660
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        806
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        821
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        91..101
FT                   /evidence="ECO:0000250"
FT   DISULFID        144..165
FT                   /evidence="ECO:0000250"
FT   DISULFID        183..198
FT                   /evidence="ECO:0000250"
FT   DISULFID        486..495
FT                   /evidence="ECO:0000250"
FT   DISULFID        501..557
FT                   /evidence="ECO:0000250"
FT   DISULFID        622..627
FT                   /evidence="ECO:0000250"
FT   DISULFID        698..711
FT                   /evidence="ECO:0000250"
FT   DISULFID        852..890
FT                   /evidence="ECO:0000250"
FT   DISULFID        897..902
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         186..195
FT                   /note="DYVKKFGENF -> GSISKYRART (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056612"
FT   VAR_SEQ         196..1032
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056613"
FT   VARIANT         634
FT                   /note="S -> T (in dbSNP:rs35322532)"
FT                   /id="VAR_047423"
FT   VARIANT         824
FT                   /note="V -> A (in dbSNP:rs1143675)"
FT                   /id="VAR_047424"
FT   VARIANT         878
FT                   /note="R -> Q (in dbSNP:rs1143676)"
FT                   /evidence="ECO:0000269|PubMed:8643114, ECO:0000269|Ref.5"
FT                   /id="VAR_003978"
FT   MUTAGEN         222
FT                   /note="T->A: Blocks binding to PLA2G2A."
FT                   /evidence="ECO:0000269|PubMed:18635536"
FT   MUTAGEN         223
FT                   /note="G->A: Blocks binding to PLA2G2A."
FT                   /evidence="ECO:0000269|PubMed:18635536"
FT   MUTAGEN         590
FT                   /note="K->Q: Abolishes almost completely cleavage."
FT                   /evidence="ECO:0000269|PubMed:1730718"
FT   MUTAGEN         591
FT                   /note="R->L: Abolishes completely cleavage."
FT                   /evidence="ECO:0000269|PubMed:1730718"
FT   MUTAGEN         1021
FT                   /note="S->A: Abolishes phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11533025"
FT   MUTAGEN         1021
FT                   /note="S->D: Reduces PXN binding."
FT                   /evidence="ECO:0000269|PubMed:11533025"
FT   MUTAGEN         1024
FT                   /note="Y->A: Disrupts PXN binding."
FT                   /evidence="ECO:0000269|PubMed:10604475"
FT   STRAND          42..45
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          54..61
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          64..71
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          87..95
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          102..104
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          127..133
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          141..145
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   TURN            152..156
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          165..168
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   HELIX           174..176
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          178..180
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   TURN            193..197
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          202..206
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          208..215
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   HELIX           218..221
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          223..229
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   TURN            230..233
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          234..237
FT                   /evidence="ECO:0007744|PDB:3V4P"
FT   STRAND          253..258
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          267..272
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   HELIX           275..277
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          280..286
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          288..298
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          308..313
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          318..320
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          322..327
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          332..334
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          338..344
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          346..349
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          351..353
FT                   /evidence="ECO:0007744|PDB:3V4P"
FT   STRAND          381..383
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          386..390
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   HELIX           393..396
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          398..403
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          415..419
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   HELIX           420..422
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          429..438
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          440..445
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          447..452
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   HELIX           453..455
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          457..461
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          466..474
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          495..505
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          511..522
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          532..534
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          536..538
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          542..554
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          556..564
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          575..583
FT                   /evidence="ECO:0007744|PDB:3V4V"
FT   STRAND          610..617
FT                   /evidence="ECO:0007744|PDB:3V4V"
SQ   SEQUENCE   1032 AA;  114900 MW;  73EC1204DE78CD35 CRC64;
     MAWEARREPG PRRAAVRETV MLLLCLGVPT GRPYNVDTES ALLYQGPHNT LFGYSVVLHS
     HGANRWLLVG APTANWLANA SVINPGAIYR CRIGKNPGQT CEQLQLGSPN GEPCGKTCLE
     ERDNQWLGVT LSRQPGENGS IVTCGHRWKN IFYIKNENKL PTGGCYGVPP DLRTELSKRI
     APCYQDYVKK FGENFASCQA GISSFYTKDL IVMGAPGSSY WTGSLFVYNI TTNKYKAFLD
     KQNQVKFGSY LGYSVGAGHF RSQHTTEVVG GAPQHEQIGK AYIFSIDEKE LNILHEMKGK
     KLGSYFGASV CAVDLNADGF SDLLVGAPMQ STIREEGRVF VYINSGSGAV MNAMETNLVG
     SDKYAARFGE SIVNLGDIDN DGFEDVAIGA PQEDDLQGAI YIYNGRADGI SSTFSQRIEG
     LQISKSLSMF GQSISGQIDA DNNGYVDVAV GAFRSDSAVL LRTRPVVIVD ASLSHPESVN
     RTKFDCVENG WPSVCIDLTL CFSYKGKEVP GYIVLFYNMS LDVNRKAESP PRFYFSSNGT
     SDVITGSIQV SSREANCRTH QAFMRKDVRD ILTPIQIEAA YHLGPHVISK RSTEEFPPLQ
     PILQQKKEKD IMKKTINFAR FCAHENCSAD LQVSAKIGFL KPHENKTYLA VGSMKTLMLN
     VSLFNAGDDA YETTLHVKLP VGLYFIKILE LEEKQINCEV TDNSGVVQLD CSIGYIYVDH
     LSRIDISFLL DVSSLSRAEE DLSITVHATC ENEEEMDNLK HSRVTVAIPL KYEVKLTVHG
     FVNPTSFVYG SNDENEPETC MVEKMNLTFH VINTGNSMAP NVSVEIMVPN SFSPQTDKLF
     NILDVQTTTG ECHFENYQRV CALEQQKSAM QTLKGIVRFL SKTDKRLLYC IKADPHCLNF
     LCNFGKMESG KEASVHIQLE GRPSILEMDE TSALKFEIRA TGFPEPNPRV IELNKDENVA
     HVLLEGLHHQ RPKRYFTIVI ISSSLLLGLI VLLLISYVMW KAGFFKRQYK SILQEENRRD
     SWSYINSKSN DD
//
